Addition of chemotherapy to standard tamoxifen treatment for postmenopausal women with node-positive* breast cancer significantly improves disease-free survival, and this benefit is maximised when ...

Some women with breast cancer may be able to safely skip chemotherapy and its uncomfortable side effects, and instead take the oral treatment tamoxifen, researchers said Tuesday. An international ...

Dec. 12 -- THURSDAY, Dec. 10 (HealthDay News) -- Adding chemotherapy to standard cancer-suppressing tamoxifen can boost survival in postmenopausal women with the most common type of breast cancer ...

Chemotherapy And Tamoxifen Reduce Risk Of Second Breast Cancer, Study Finds. ScienceDaily . Retrieved April 29, 2025 from www.sciencedaily.com / releases / 2007 / 12 / 071226003841.htm ...

Albain et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.

However, chemotherapy use is associated with an increased risk of stroke, regardless of tamoxifen use. Tamoxifen has been used for the treatment of postmenopausal breast cancer since 1978.

Background: Tamoxifen is standard adjuvant treatment for postmenopausal women with hormone-receptor-positive breast cancer. We assessed the benefit of adding chemotherapy to adjuvant tamoxifen and ...

Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer Adjuvant chemotherapy ...

"Since the adjuvant chemotherapy causes ovarian suppression in many premenopausal patients," he said, "these patients then in fact received ovarian suppression plus tamoxifen," rather than ...

Adjuvant tamoxifen treatment given after chemotherapy extends disease-free and overall survival for oestrogen receptor-positive breast cancer (Early Breast Cancer Trialists‘ Collaborative Group ...

Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor–positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain.